Chinese expert consensus on the clinical diagnosis and management of ocular myasthenia gravis (2025)_Chinese Journal of Ocular Fundus Diseases

Authors：

 Expert Workgroup of “Chinese Expert Consensus on the Clinical Diagnosis and Management of Ocular Myasthenia Gravis (2025)” ,  Neuro-Ophthalmology Group of Ophthalmology Branch of Chinese Medical Association , Neuro-Ophthalmology Society of Chinese Research Hospital Association

Corresponding?author：

Expert Workgroup of “Chinese Expert Consensus on the Clinical Diagnosis and Management of Ocular Myasthenia Gravis (2025)”, Email: weishihui706@hotmail.com; Neuro-Ophthalmology Group of Ophthalmology Branch of Chinese Medical Association, Email: wusongdi@gmail.com

Keywords：

Myasthenia gravis; Ocular myasthenia gravis; Generalized transformation; Refractory myasthenia gravis; Clinical diagnosis and management; Expert consensus

DOI：

10.3760/cma.j.cn511434-20250707-00298

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Myasthenia gravis (MG) is an autoimmune disease characterized by antibody-mediated acquired neuromuscular junction transmission disorders. Based on the different muscles involved, MG can be classified into ocular MG (OMG) and generalized MG. Eighty percent of MG patients initially present with OMG, leading to ptosis and diplopia, which significantly impair their quality of life. Approximately 50% to 69.7% of OMG patients may progress to generalized MG within two years, exhibiting symptoms such as limb weakness, dysphagia, and even respiratory failure that threatens life. Due to the diverse manifestations and fluctuating symptoms of OMG, it is often prone to missed and/or misdiagnosis. To further standardize the understanding of OMG among neuro-ophthalmologists, Neuro-Ophthalmology Group of Ophthalmology Branch of Chinese Medical Association, Neuro-Ophthalmology Society of Chinese Research Hospital Association, in conjunction with relevant domestic and international literature and guideline consensuses and based on the actual situation in China, have developed the Chinese Expert Consensus on the Clinical Diagnosis and Management of Ocular Myasthenia Gravis (2025). The consensus comprehensively covers clinical diagnosis and management of OMG, including epidemiology, mechanisms of ocular extraocular muscle involvement in MG, clinical manifestations, auxiliary examinations, diagnosis, differential diagnosis, treatment, assessment and prevention strategies for generalized transformation of OMG, and diagnosis and management of refractory OMG, with detailed recommendations provided in nine sections. This consensus is applicable to ophthalmologists, neuro-ophthalmologists, neurologists, and medical personnel engaged in the diagnosis and management of OMG. It aims to standardize the diagnosis and management process of OMG, improve early identification and treatment capabilities, alleviate ocular symptoms of OMG and reduce the risk of generalized transformation.

1.	Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies[J]. Nat Rev Neurol, 2024, 20(2): 84-98. DOI: 1038/s41582-023-00916-w. DOI: 10.1038/s41582-023-00916-w.
2.	中國免疫學會神經免疫分會. 中國重癥肌無力診斷和治療指南(2020版)[J]. 中國神經免疫學和神經病學雜志, 2021, 28(1): 1-12. DOI: 10.14166/j.issn.1671-2420.2024.05.004.Neuroimmunology Branch of the Chinese Society for Immunology. Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 edition)[J]. Chin J Neuroimmunol & Neurol, 2021, 28(1): 1-12. DOI: 10.14166/j.issn.1671-2420.2024.05.004.
3.	Behbehani R. Ocular myasthenia gravis: a current overview[J]. Eye Brain, 2023, 15: 1-13. DOI: 10.2147/eb.S389629.
4.	Hendricks TM, Bhatti MT, Hodge DO, et al. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study[J]. Am J Ophthalmol, 2019, 205: 99-105. DOI: 10.1016/j.ajo.2019.04.017.
5.	Nagia L, Lemos J, Abusamra K, et al. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis[J]. Ophthalmology, 2015, 122(7): 1517-1521. DOI: 10.1016/j.ophtha.2015.03.010.
6.	Zhu Y, Wang B, Hao Y, et al. Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases[J/OL]. Front Immunol, 2023, 14: 1223322[2023-09-14]. https://pubmed.ncbi.nlm.nih.gov/37781409/. DOI: 10.3389/fimmu.2023.1223322.
7.	Menon D, Alharbi M, Katzberg HD, et al. Effect of immunosuppression in risk of developing generalized symptoms in ocular myasthenia gravis: a retrospective cohort study[J/OL]. Neurology, 2024, 103(4): e209722[2024-08-27]. https://pubmed.ncbi.nlm.nih.gov/39079067/. DOI: 10.1212/WNL.0000000000209722.
8.	Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis[J]. Muscle Nerve, 2008, 37(2): 141-149. DOI: 10.1002/mus.20950.
9.	Narita T, Nakane S, Nagaishi A, et al. Immunotherapy for ocular myasthenia gravis: an observational study in Japan[J/OL]. Ther Adv Neurol Disord, 2023, 16: 17562864231163819[2023-04-04]. https://pubmed.ncbi.nlm.nih.gov/37051222/. DOI: 10.1177/17562864231163819.
10.	Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies[J/OL]. Ther Adv Neurol Disord, 2018, 11: 1756285617749134[2018-01-18]. https://pubmed.ncbi.nlm.nih.gov/29403543/. DOI: 10.1177/1756285617749134.
11.	Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary[J]. Neurology, 2016, 87(4): 419-425. DOI: 10.1212/wnl.0000000000002790.
12.	Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study[J/OL]. Lancet Reg Health West Pac, 2020, 5: 100063[2020-11-27]. https://pubmed.ncbi.nlm.nih.gov/34327399/. DOI: 10.1016/j.lanwpc.2020.100063.
13.	Evoli A, Iorio R. Controversies in ocular myasthenia gravis[J/OL]. Front Neurol, 2020, 11: 605902[2020-11-30]. https://pubmed.ncbi.nlm.nih.gov/33329368/. DOI: 10.3389/fneur.2020.605902.
14.	Guan YZ, Cui LY, Liu MS, et al. Single-fiber electromyography in the extensor digitorum communis for the predictive prognosis of ocular myasthenia gravis: a retrospective study of 102 cases[J]. Chin Med J (Engl), 2015, 128(20): 2783-2786. DOI: 10.4103/0366-6999.167354.
15.	Al-Haidar M, Benatar M, Kaminski HJ. Ocular myasthenia[J]. Neurol Clin, 2018, 36(2): 241-251. DOI: 10.1016/j.ncl.2018.01.003.
16.	Liu R, Xu H, Wang G, et al. Extraocular muscle characteristics related to myasthenia gravis susceptibility[J/OL]. PLoS One, 2013, 8(2): e55611[2013-02-08]. https://pubmed.ncbi.nlm.nih.gov/23409007/. DOI: 10.1371/journal.pone.0055611.
17.	Peeler CE, De Lott LB, Nagia L, et al. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis[J]. JAMA Neurol, 2015, 72(10): 1170-1174. DOI: 10.1001/jamaneurol.2015.1444.
18.	Barton JJ, Fouladvand M. Ocular aspects of myasthenia gravis[J]. Semin Neurol, 2000, 20(1): 7-20. DOI: 10.1055/s-2000-6829.
19.	Elrod RD, Weinberg DA. Ocular myasthenia gravis[J]. Ophthalmol Clin North Am, 2004, 17(3): 275-309. DOI: 10.1016/j.ohc.2004.05.014.
20.	Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America[J]. Neurology, 2000, 55(1): 16-23. DOI: 10.1212/wnl.55.1.16.
21.	Kee HJ, Yang HK, Hwang JM, et al. Evaluation and validation of sustained upgaze combined with the ice-pack test for ocular myasthenia gravis in Asians[J]. Neuromuscul Disord, 2019, 29(4): 296-301. DOI: 10.1016/j.nmd.2018.12.011.
22.	Pietris J, Madike R, Lam A, et al. Cogan's lid twitch for myasthenia gravis: a systematic review[J]. Semin Ophthalmol, 2023, 38(8): 727-736. DOI: 10.1080/08820538.2023.2211134.
23.	Gay AJ, Salmon ML, Windsor CE. Hering's law, the levators, and their relationship in disease states[J]. Arch Ophthalmol, 1967, 77(2): 157-160. DOI: 10.1001/archopht.1967.00980020159002.
24.	Kubis KC, Danesh-Meyer HV, Savino PJ, et al. The ice test versus the rest test in myasthenia gravis[J]. Ophthalmology, 2000, 107(11): 1995-1998. DOI: 10.1016/s0161-6420(00)00458-9.
25.	Benatar M. A systematic review of diagnostic studies in myasthenia gravis[J]. Neuromuscul Disord, 2006, 16(7): 459-467. DOI: 10.1016/j.nmd.2006.05.006.
26.	Cheo SW, Low QJ, Mow WC, et al. Ice pack test-an useful bedside test to diagnose myasthenia gravis[J]. QJM, 2019, 112(5): 381-382. DOI: 10.1093/qjmed/hcy284.
27.	Proudman W, Kleinig O, Lam L, et al. The icepack test in the diagnosis of myasthenia gravis with ocular features: a systematic review of diagnostic accuracy, technique, and economic utilit[J]. Semin Ophthalmol, 2023, 38(7): 679-685. DOI: 10.1080/08820538.2023.2194984.
28.	彭丹濤, 許賢豪, 佘子瑜. 新斯的明試驗改良結果判定法研究[J]. 中國神經免疫學和神經病學雜志, 2007, 14(1): 3. DOI: 10.3969/j.issn.1006-2963.2007.01.001.Peng DT, Xu XH, She ZY. Study on revive criteria for neostigmine test[J]. Chin J Neuroimmunol & Neurol, 2007, 14(1): 3. DOI: 10.3969/j.issn.1006-2963.2007.01.001.
29.	Prasad S, Halmagyi GM. A new test for ocular myasthenia gravis? OMG![J]. Neurology, 2016, 86(7): 590-591. DOI: 10.1212/wnl.0000000000002380.
30.	Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis[J/OL]. BMC Neurol, 2010, 10: 46[2010-06-18]. https://pubmed.ncbi.nlm.nih.gov/20565885/. DOI: 10.1186/1471-2377-10-46.
31.	Abraham A, Alabdali M, Alsulaiman A, et al. Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis[J]. Muscle Nerve, 2017, 55(2): 166-170. DOI: 10.1002/mus.25214.
32.	Kim KH, Kim SW, Shin HY. Initial repetitive nerve stimulation test predicts conversion of ocular myasthenia gravis to generalized myasthenia gravis[J]. J Clin Neurol, 2021, 17(2): 265-272. DOI: 10.3988/jcn.2021.17.2.265.
33.	Cherian A, Baheti NN, Iype T. Electrophysiological study in neuromuscular junction disorders[J]. Ann Indian Acad Neurol, 2013, 16(1): 34-41. DOI: 10.4103/0972-2327.107690.
34.	St?lberg E, van Dijk H, Falck B, et al. Standards for quantification of EMG and neurography[J]. Clin Neurophysiol, 2019, 130(9): 1688-1729. DOI: 10.1016/j.clinph.2019.05.008.
35.	Giannoccaro MP, Di Stasi V, Zanesini C, et al. Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation[J]. J Neurol, 2020, 267(3): 739-745. DOI: 10.1007/s00415-019-09631-3.
36.	Sanders DB, Arimura K, Cui L, et al. Guidelines for single fiber EMG[J]. Clin Neurophysiol, 2019, 130(8): 1417-1439. DOI: 10.1016/j.clinph.2019.04.005.
37.	Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics[J/OL]. Front Immunol, 2020, 11: 212[2020-02-14]. https://pubmed.ncbi.nlm.nih.gov/32117321/. DOI: 10.3389/fimmu.2020.00212.
38.	Fang CEH, Bokre D, Wong SH. Clinical characteristics associated with secondary generalization in patients with ocular myasthenia gravis: a systematic review and meta-analysis[J/OL]. Neurology, 2023, 101(16): e1594-e1605[2023-10-17]. https://pubmed.ncbi.nlm.nih.gov/37643888/. DOI: 10.1212/WNL.0000000000207642.
39.	Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations[J/OL]. J Clin Med, 2021, 10(11): 2235[2021-05-21]. https://pubmed.ncbi.nlm.nih.gov/34064035/. DOI: 10.3390/jcm10112235.
40.	Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management[J/OL]. Front Neurol, 2020, 11: 596981[2020-11-30]. https://pubmed.ncbi.nlm.nih.gov/33329350/. DOI: 10.3389/fneur.2020.596981.
41.	Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis[J]. J Autoimmun, 2014, 52: 139-145. DOI: 10.1016/j.jaut.2013.12.004.
42.	Li F, Hotter B, Swierzy M, et al. Generalization after ocular onset in myasthenia gravis: a case series in Germany[J]. J Neurol, 2018, 265(12): 2773-2782. DOI: 10.1007/s00415-018-9056-8.
43.	Gengadharan PN, Ong WT, Tan JY, et al. Ocular myasthenia gravis: determining the predictive factors of secondary generalisation[J]. Acta Neurol Belg, 2025, 125(2): 351-358. DOI: 10.1007/s13760-024-02693-9.
44.	Marom EM. Imaging thymoma[J]. J Thorac Oncol, 2010, 5(10 Suppl 4): S296-303. DOI: 10.1097/JTO.0b013e3181f209ca.
45.	Strange CD, Ahuja J, Shroff GS, et al. Imaging evaluation of thymoma and thymic carcinoma[J/OL]. Front Oncol, 2021, 11: 810419[2022-01-03]. https://pubmed.ncbi.nlm.nih.gov/35047412/. DOI: 10.3389/fonc.2021.810419.
46.	Díaz-Manera J, Luna S, Roig C. Ocular ptosis: differential diagnosis and treatment[J]. Curr Opin Neurol, 2018, 31(5): 618-627. DOI: 10.1097/wco.0000000000000600.
47.	Dagi LR, Velez FG, Archer SM, et al. Adult strabismus preferred practice pattern?[J]. Ophthalmology, 2020, 127(1): 182-198. DOI: 10.1016/j.ophtha.2019.09.023.
48.	Gunton KB, Wasserman BN, DeBenedictis C. Strabismus[J]. Prim Care, 2015, 42(3): 393-407. DOI: 10.1016/j.pop.2015.05.006.
49.	Lekskul A, Chotkajornkiat N, Wuthisiri W, et al. Acute acquired comitant esotropia: etiology, clinical course, and management[J]. Clin Ophthalmol, 2021, 15: 1567-1572. DOI: 10.2147/opth.S307951.
50.	Ali A, Esmaeil A, Behbehani R. Mitochondrial chronic progressive external ophthalmoplegia[J/OL]. Brain Sci, 2024, 14(2): 135[2024-01-27]. https://pubmed.ncbi.nlm.nih.gov/38391710/. DOI: 10.3390/brainsci14020135.
51.	Bartalena L, Gallo D, Tanda ML, et al. Thyroid eye disease: epidemiology, natural history, and risk factors[J]. Ophthalmic Plast Reconstr Surg, 2023, 39(6S): 2-8. DOI: 10.1097/iop.0000000000002467.
52.	Julie MS, Shanlee S, Michael K. Thyroid eye disease and ocular myasthenia gravis[J]. Curr Opin Neurol, 2024, 38(1): 71-78. DOI: 10.1097/wco.0000000000001339.
53.	Fang Y, Shen B, Dai Q, et al. Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment[J/OL]. Eur J Med Res, 2023, 28(1): 395[2023-10-04]. https://pubmed.ncbi.nlm.nih.gov/37794419/. DOI: 10.1186/s40001-023-01330-0.
54.	Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease[J/OL]. BMJ, 2020, 369: 1067[2020-06-16]. https://pubmed.ncbi.nlm.nih.gov/32546500/. DOI: 10.1136/bmj.m1067.
55.	Yamashita S. Recent progress in oculopharyngeal muscular dystrophy[J/OL]. J Clin Med, 2021, 10(7): 1375[2021-03-29]. https://pubmed.ncbi.nlm.nih.gov/33805441/. DOI: 10.3390/jcm10071375.
56.	Ramdas S, Beeson D, Dong YY. Congenital myasthenic syndromes: increasingly complex[J]. Curr Opin Neurol, 2024, 37(5): 493-501. DOI: 10.1097/wco.0000000000001300.
57.	Jagtap SA, Abraham K, Sarada C, et al. Congenital myasthenic syndromes: natural history and long-term prognosis[J]. Ann Indian Acad Neurol, 2013, 16(3): 338-341. DOI: 10.4103/0972-2327.116918.
58.	Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes[J/OL]. Ther Adv Neurol Disord, 2023, 16: 17562864231213240[2023-12-26]. https://pubmed.ncbi.nlm.nih.gov/38152089/. DOI: 10.1177/17562864231213240.
59.	Punga AR, Maddison P, Heckmann JM, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders[J]. Lancet Neurol, 2022, 21(2): 176-188. DOI: 10.1016/s1474-4422(21)00297-0.
60.	Kumar R, Singh BR. Botulinum toxin: a comprehensive review of its molecular architecture and mechanistic action[J/OL]. Int J Mol Sci, 2025, 26(2): 777[2025-01-17]. https://pubmed.ncbi.nlm.nih.gov/39859491/. DOI: 10.3390/ijms26020777.
61.	Nestor MS, Han H, Gade A, et al. Botulinum toxin-induced blepharoptosis: anatomy, etiology, prevention, and therapeutic options[J]. J Cosmet Dermatol, 2021, 20(10): 3133-3146. DOI: 10.1111/jocd.14361.
62.	Dell'Antonia M, Mugheddu C, Ferreli C, et al. Do not forget about myasthenia gravis when performing botulinum toxin injections[J/OL]. J Eur Acad Dermatol Venereol, 2023, 8: e1070-e1071[2023-04-15]. https://pubmed.ncbi.nlm.nih.gov/37060273/. DOI: 10.1111/jdv.19115.
63.	Tamhankar MA, Volpe NJ. Management of acute cranial nerve 3, 4 and 6 palsies: role of neuroimaging[J]. Curr Opin Ophthalmol, 2015, 26(6): 464-468. DOI: 10.1097/icu.0000000000000200.
64.	Weidauer S, Hofmann C, Wagner M, et al. Neuroradiological and clinical features in ophthalmoplegia[J]. Neuroradiology, 2019, 61(4): 365-387. DOI: 10.1007/s00234-019-02183-3.
65.	Kline LB, Demer JL, Vaphiades MS, et al. Disorders of the fourth cranial nerve[J]. J Neuroophthalmol, 2021, 41(2): 176-193. DOI: 10.1097/wno.0000000000001261.
66.	Martin TJ. Horner syndrome: a clinical review[J]. ACS Chem Neurosci, 2017, 9(2): 177-186. DOI: 10.1021/acschemneuro.7b00405.
67.	Noioso CM, Bevilacqua L, Acerra GM, et al. Miller Fisher syndrome: an updated narrative review[J/OL]. Front Neurol, 2023, 14: 1250774[2023-08-24]. https://pubmed.ncbi.nlm.nih.gov/37693761/. DOI: 10.3389/fneur.2023.1250774.
68.	Wakerley BR, Uncini A, Yuki N. Guillain-Barré and Miller Fisher syndromes--new diagnostic classification[J]. Nat Rev Neurol, 2014, 10(9): 537-544. DOI: 10.1038/nrneurol.2014.138.
69.	Soares J, Brigham de Figueiredo M, Prior AR, et al. Jaw winking synkinesis[J/OL]. J Pediatr, 2019, 210: 234[2019-04-19]. https://pubmed.ncbi.nlm.nih.gov/31010588/. DOI: 10.1016/j.jpeds.2019.03.029.
70.	Dietz E. Ophthalmoplegia: definition and clinical diagnostic techniques[J]. J Binocul Vis Ocul Motil, 2018, 68(1): 4-6. DOI: 10.1080/2576117x.2017.1416239.
71.	Zeppieri M, Ameer MA, Jahngir MU, et al. Meige Syndrome[M/OL]. Treasure Island (FL): StatPearls Publishing, 2025[2025-01-01]. https://pubmed.ncbi.nlm.nih.gov/30020730/.
72.	Kerty E, Elsais A, Argov Z, et al. EFNS/ENS guidelines for the treatment of ocular myasthenia[J]. Eur J Neurol, 2014, 21(5): 687-693. DOI: 10.1111/ene.12359.
73.	Katz NK, Barohn RJ. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis[J/OL]. Neuropharmacology, 2021, 182: 108303[2020-09-09]. https://pubmed.ncbi.nlm.nih.gov/32918950/. DOI: 10.1016/j.neuropharm.2020.108303.
74.	Sharshar T, Porcher R, Demeret S, et al. Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial[J]. JAMA Neurol, 2021, 78(4): 426-433. DOI: 10.1001/jamaneurol.2020.5407.
75.	Uzawa A, Suzuki S, Kuwabara S, et al. Impact of early treatment with intravenous high-dose methylprednisolone for ocular myasthenia gravis[J]. Neurotherapeutics, 2023, 20(2): 518-523. DOI: 10.1007/s13311-022-01335-3.
76.	Zhang KY, Duan WW, Luo YB, et al. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study[J/OL]. Orphanet J Rare Dis, 2024, 19(1): 19[2024-01-19]. https://pubmed.ncbi.nlm.nih.gov/38243274/. DOI: 10.1186/s13023-024-03025-z.
77.	中華醫學會兒科學分會神經學組. 兒童神經系統疾病糖皮質激素治療專家系列建議之五——重癥肌無力的治療[J]. 中國實用兒科雜志, 2022, 37(5): 340-343. DOI: 10.19538/j.ek2022050606.Neurology Group, Pediatrics Branch, Chinese Medical Association. The fifth expert recommendation in the series of glucocorticoid therapy for children's neurological diseases - treatment of myasthenia gravis[J]. Chin J Pract Pediatr, 2022, 37(5): 340-343. DOI: 10.19538/j.ek2022050606.
78.	Benatar M, Sanders DB, Wolfe GI, et al. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial[J]. Ann NY Acad Sci, 2012, 1275: 17-22. DOI: 10.1111/j.1749-6632.2012.06780.x.
79.	Witte AS, Cornblath DR, Parry GJ, et al. Azathioprine in the treatment of myasthenia gravis[J]. Ann Neurol, 1984, 15(6): 602-605. DOI: 10.1002/ana.410150615.
80.	Duan W, Peng Y, Jin W, et al. Tacrolimus as single-agent immunotherapy and minimal manifestation status in nonthymoma myasthenia gravis[J/OL]. J Immunol Res, 2021, 2021: 9138548[2021-11-20]. https://pubmed.ncbi.nlm.nih.gov/34845439/. DOI: 10.1155/2021/9138548.
81.	Fan Z, Lei L, Su S, et al. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis[J]. Ann Clin Transl Neurol, 2023, 10(4): 589-598. DOI: 10.1002/acn3.51746.
82.	Ciafaloni E, Nikhar NK, Massey JM, et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis[J]. Neurology, 2000, 55(3): 448-450. DOI: 10.1212/wnl.55.3.448.
83.	Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis[J/OL]. Cochrane Database Syst Rev, 2007, (4): CD005224[2007-10-17]. https://pubmed.ncbi.nlm.nih.gov/17943844/. DOI: 10.1002/14651858.CD005224.pub2.
84.	Chan JW. Mycophenolate mofetil for ocular myasthenia[J]. J Neurol, 2008, 255(4): 510-513. DOI: 10.1007/s00415-008-0718-9.
85.	Cornblath WT. Treatment of ocular myasthenia gravis[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(4): 257-259. DOI: 10.22608/APO.2018301.
86.	Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update[J]. Neurology, 2021, 96(3): 114-122. DOI: 10.1212/wnl.0000000000011124.
87.	De Feo LG, Schottlender J, Martelli NA, et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis[J]. Muscle Nerve, 2002, 26(1): 31-36. DOI: 10.1002/mus.10133.
88.	Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial[J]. JAMA Neurol, 2022, 79(11): 1105-1112. DOI: 10.1001/jamaneurol.2022.2887.
89.	Chuquilin M, Barohn R. Rituximab in newly diagnosed generalized myasthenia gravis: a new treatment paradigm?[J]. JAMA Neurol, 2022, 79(11): 1100-1102. DOI: 10.1001/jamaneurol.2022.2311.
90.	Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab[J]. Neuromuscul Disord, 2017, 27(6): 565-568. DOI: 10.1016/j.nmd.2017.03.007.
91.	Ma Y, Nie X, Zhu G, et al. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and bayesian network meta-analysis[J]. CNS Drugs, 2024, 38(2): 93-104. DOI: 10.1007/s40263-024-01062-7.
92.	Howard JF Jr, Vu T, Li G, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)[J/OL]. Neurotherapeutics, 2024, 21(5): e00378[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/39227284/. DOI: 10.1016/j.neurot.2024.e00378.
93.	Ma T, Zhu Y, Zhu R. Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases[J/OL]. Front Immunol, 2024, 15: 1497398[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/39872535/. DOI: 10.3389/fimmu.2024.1497398.
94.	Liu Z, Feng H, Yeung SC, et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis[J]. Ann Thorac Surg, 2011, 92(6): 1993-1999. DOI: 10.1016/j.athoracsur.2011.08.001.
95.	Liu X, Zhou W, Hu J, et al. Prognostic predictors of remission in ocular myasthenia after thymectomy[J]. J Thorac Dis, 2020, 12(3): 422-430. DOI: 10.21037/jtd.2020.01.17.
96.	Wilson L, Davis H. The role of thymoma and thymic hyperplasia as prognostic risk factors for secondary generalisation in adults with ocular myasthenia gravis: a systematic narrative review[J]. Br Ir Orthopt J, 2023, 19(1): 108-119. DOI: 10.22599/bioj.315.
97.	Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: association of British Neurologists' management guidelines[J]. Pract Neurol, 2015, 15(3): 199-206. DOI: 10.1136/practneurol-2015-001126.
98.	Litwin AS, Patel B, McNab AA, et al. Blepharoptosis surgery in patients with myasthenia gravis[J]. Br J Ophthalmol, 2015, 99(7): 899-902. DOI: 10.1136/bjophthalmol-2014-306335.
99.	Witthayaweerasak J, Rattanalert N, Aui-Aree N. Prognostic factors for conversion to generalization in ocular myasthenia gravis[J/OL]. Medicine (Baltimore), 2021, 100(19): e25899[2021-05-14]. https://pubmed.ncbi.nlm.nih.gov/34106649/. DOI: 10.1097/MD.0000000000025899.
100.	Wong SH, Huda S, Vincent A, et al. Ocular myasthenia gravis: controversies and updates[J/OL]. Curr Neurol Neurosci Rep, 2014, 14(1): 421[2014-01-01]. https://pubmed.ncbi.nlm.nih.gov/24272275/. DOI: 10.1007/s11910-013-0421-9.
101.	Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis[J]. Arch Neurol, 2003, 60(2): 243-248. DOI: 10.1001/archneur.60.2.243.
102.	Li M, Ge F, Guo R, et al. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis[J/OL]. Ther Adv Neurol Disord, 2019, 12: 1756286419876521[2019-09-14]. https://pubmed.ncbi.nlm.nih.gov/35173803/. DOI: 10.1177/1756286419876521.
103.	Ruan Z, Guo R, Zhou H, et al. Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a propensity score analysis[J]. Eur J Neurol, 2022, 29(6): 1805-1814. DOI: 10.1111/ene.15292.
104.	中國罕見病聯盟神經罕見病專業委員會, 中國罕見病聯盟重癥肌無力協作組, 中華醫學會神經病學分會神經肌肉病學組. 中國難治性全身型重癥肌無力診斷和治療專家共識(2024版)[J]. 中華神經科雜志, 2024, 57(8): 840-847. DOI: 10.3760/cma.j.cn113694-20240222-00106.Neurorare Disease Professional Committee of China Rare Disease Alliance, Myasthenia Gravis Collaborative Group of China Rare Disease Alliance, Neuromuscular Disease Group of Neurology Branch, Chinese Medical Association. Expert consensus for diagnosis and treatment of refractory generalized myasthenia gravis in China (2024)[J]. Chin J Neurol, 2024, 57(8): 840-847. DOI: 10.3760/cma.j.cn113694-20240222-00106.

1. Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies[J]. Nat Rev Neurol, 2024, 20(2): 84-98. DOI: 1038/s41582-023-00916-w. DOI: 10.1038/s41582-023-00916-w.
2. 中國免疫學會神經免疫分會. 中國重癥肌無力診斷和治療指南(2020版)[J]. 中國神經免疫學和神經病學雜志, 2021, 28(1): 1-12. DOI: 10.14166/j.issn.1671-2420.2024.05.004.Neuroimmunology Branch of the Chinese Society for Immunology. Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 edition)[J]. Chin J Neuroimmunol & Neurol, 2021, 28(1): 1-12. DOI: 10.14166/j.issn.1671-2420.2024.05.004.
3. Behbehani R. Ocular myasthenia gravis: a current overview[J]. Eye Brain, 2023, 15: 1-13. DOI: 10.2147/eb.S389629.
4. Hendricks TM, Bhatti MT, Hodge DO, et al. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study[J]. Am J Ophthalmol, 2019, 205: 99-105. DOI: 10.1016/j.ajo.2019.04.017.
5. Nagia L, Lemos J, Abusamra K, et al. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis[J]. Ophthalmology, 2015, 122(7): 1517-1521. DOI: 10.1016/j.ophtha.2015.03.010.
6. Zhu Y, Wang B, Hao Y, et al. Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases[J/OL]. Front Immunol, 2023, 14: 1223322[2023-09-14]. https://pubmed.ncbi.nlm.nih.gov/37781409/. DOI: 10.3389/fimmu.2023.1223322.
7. Menon D, Alharbi M, Katzberg HD, et al. Effect of immunosuppression in risk of developing generalized symptoms in ocular myasthenia gravis: a retrospective cohort study[J/OL]. Neurology, 2024, 103(4): e209722[2024-08-27]. https://pubmed.ncbi.nlm.nih.gov/39079067/. DOI: 10.1212/WNL.0000000000209722.
8. Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis[J]. Muscle Nerve, 2008, 37(2): 141-149. DOI: 10.1002/mus.20950.
9. Narita T, Nakane S, Nagaishi A, et al. Immunotherapy for ocular myasthenia gravis: an observational study in Japan[J/OL]. Ther Adv Neurol Disord, 2023, 16: 17562864231163819[2023-04-04]. https://pubmed.ncbi.nlm.nih.gov/37051222/. DOI: 10.1177/17562864231163819.
10. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies[J/OL]. Ther Adv Neurol Disord, 2018, 11: 1756285617749134[2018-01-18]. https://pubmed.ncbi.nlm.nih.gov/29403543/. DOI: 10.1177/1756285617749134.
11. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary[J]. Neurology, 2016, 87(4): 419-425. DOI: 10.1212/wnl.0000000000002790.
12. Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study[J/OL]. Lancet Reg Health West Pac, 2020, 5: 100063[2020-11-27]. https://pubmed.ncbi.nlm.nih.gov/34327399/. DOI: 10.1016/j.lanwpc.2020.100063.
13. Evoli A, Iorio R. Controversies in ocular myasthenia gravis[J/OL]. Front Neurol, 2020, 11: 605902[2020-11-30]. https://pubmed.ncbi.nlm.nih.gov/33329368/. DOI: 10.3389/fneur.2020.605902.
14. Guan YZ, Cui LY, Liu MS, et al. Single-fiber electromyography in the extensor digitorum communis for the predictive prognosis of ocular myasthenia gravis: a retrospective study of 102 cases[J]. Chin Med J (Engl), 2015, 128(20): 2783-2786. DOI: 10.4103/0366-6999.167354.
15. Al-Haidar M, Benatar M, Kaminski HJ. Ocular myasthenia[J]. Neurol Clin, 2018, 36(2): 241-251. DOI: 10.1016/j.ncl.2018.01.003.
16. Liu R, Xu H, Wang G, et al. Extraocular muscle characteristics related to myasthenia gravis susceptibility[J/OL]. PLoS One, 2013, 8(2): e55611[2013-02-08]. https://pubmed.ncbi.nlm.nih.gov/23409007/. DOI: 10.1371/journal.pone.0055611.
17. Peeler CE, De Lott LB, Nagia L, et al. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis[J]. JAMA Neurol, 2015, 72(10): 1170-1174. DOI: 10.1001/jamaneurol.2015.1444.
18. Barton JJ, Fouladvand M. Ocular aspects of myasthenia gravis[J]. Semin Neurol, 2000, 20(1): 7-20. DOI: 10.1055/s-2000-6829.
19. Elrod RD, Weinberg DA. Ocular myasthenia gravis[J]. Ophthalmol Clin North Am, 2004, 17(3): 275-309. DOI: 10.1016/j.ohc.2004.05.014.
20. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America[J]. Neurology, 2000, 55(1): 16-23. DOI: 10.1212/wnl.55.1.16.
21. Kee HJ, Yang HK, Hwang JM, et al. Evaluation and validation of sustained upgaze combined with the ice-pack test for ocular myasthenia gravis in Asians[J]. Neuromuscul Disord, 2019, 29(4): 296-301. DOI: 10.1016/j.nmd.2018.12.011.
22. Pietris J, Madike R, Lam A, et al. Cogan's lid twitch for myasthenia gravis: a systematic review[J]. Semin Ophthalmol, 2023, 38(8): 727-736. DOI: 10.1080/08820538.2023.2211134.
23. Gay AJ, Salmon ML, Windsor CE. Hering's law, the levators, and their relationship in disease states[J]. Arch Ophthalmol, 1967, 77(2): 157-160. DOI: 10.1001/archopht.1967.00980020159002.
24. Kubis KC, Danesh-Meyer HV, Savino PJ, et al. The ice test versus the rest test in myasthenia gravis[J]. Ophthalmology, 2000, 107(11): 1995-1998. DOI: 10.1016/s0161-6420(00)00458-9.
25. Benatar M. A systematic review of diagnostic studies in myasthenia gravis[J]. Neuromuscul Disord, 2006, 16(7): 459-467. DOI: 10.1016/j.nmd.2006.05.006.
26. Cheo SW, Low QJ, Mow WC, et al. Ice pack test-an useful bedside test to diagnose myasthenia gravis[J]. QJM, 2019, 112(5): 381-382. DOI: 10.1093/qjmed/hcy284.
27. Proudman W, Kleinig O, Lam L, et al. The icepack test in the diagnosis of myasthenia gravis with ocular features: a systematic review of diagnostic accuracy, technique, and economic utilit[J]. Semin Ophthalmol, 2023, 38(7): 679-685. DOI: 10.1080/08820538.2023.2194984.
28. 彭丹濤, 許賢豪, 佘子瑜. 新斯的明試驗改良結果判定法研究[J]. 中國神經免疫學和神經病學雜志, 2007, 14(1): 3. DOI: 10.3969/j.issn.1006-2963.2007.01.001.Peng DT, Xu XH, She ZY. Study on revive criteria for neostigmine test[J]. Chin J Neuroimmunol & Neurol, 2007, 14(1): 3. DOI: 10.3969/j.issn.1006-2963.2007.01.001.
29. Prasad S, Halmagyi GM. A new test for ocular myasthenia gravis? OMG![J]. Neurology, 2016, 86(7): 590-591. DOI: 10.1212/wnl.0000000000002380.
30. Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis[J/OL]. BMC Neurol, 2010, 10: 46[2010-06-18]. https://pubmed.ncbi.nlm.nih.gov/20565885/. DOI: 10.1186/1471-2377-10-46.
31. Abraham A, Alabdali M, Alsulaiman A, et al. Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis[J]. Muscle Nerve, 2017, 55(2): 166-170. DOI: 10.1002/mus.25214.
32. Kim KH, Kim SW, Shin HY. Initial repetitive nerve stimulation test predicts conversion of ocular myasthenia gravis to generalized myasthenia gravis[J]. J Clin Neurol, 2021, 17(2): 265-272. DOI: 10.3988/jcn.2021.17.2.265.
33. Cherian A, Baheti NN, Iype T. Electrophysiological study in neuromuscular junction disorders[J]. Ann Indian Acad Neurol, 2013, 16(1): 34-41. DOI: 10.4103/0972-2327.107690.
34. St?lberg E, van Dijk H, Falck B, et al. Standards for quantification of EMG and neurography[J]. Clin Neurophysiol, 2019, 130(9): 1688-1729. DOI: 10.1016/j.clinph.2019.05.008.
35. Giannoccaro MP, Di Stasi V, Zanesini C, et al. Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation[J]. J Neurol, 2020, 267(3): 739-745. DOI: 10.1007/s00415-019-09631-3.
36. Sanders DB, Arimura K, Cui L, et al. Guidelines for single fiber EMG[J]. Clin Neurophysiol, 2019, 130(8): 1417-1439. DOI: 10.1016/j.clinph.2019.04.005.
37. Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics[J/OL]. Front Immunol, 2020, 11: 212[2020-02-14]. https://pubmed.ncbi.nlm.nih.gov/32117321/. DOI: 10.3389/fimmu.2020.00212.
38. Fang CEH, Bokre D, Wong SH. Clinical characteristics associated with secondary generalization in patients with ocular myasthenia gravis: a systematic review and meta-analysis[J/OL]. Neurology, 2023, 101(16): e1594-e1605[2023-10-17]. https://pubmed.ncbi.nlm.nih.gov/37643888/. DOI: 10.1212/WNL.0000000000207642.
39. Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations[J/OL]. J Clin Med, 2021, 10(11): 2235[2021-05-21]. https://pubmed.ncbi.nlm.nih.gov/34064035/. DOI: 10.3390/jcm10112235.
40. Lazaridis K, Tzartos SJ. Myasthenia gravis: autoantibody specificities and their role in MG management[J/OL]. Front Neurol, 2020, 11: 596981[2020-11-30]. https://pubmed.ncbi.nlm.nih.gov/33329350/. DOI: 10.3389/fneur.2020.596981.
41. Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis[J]. J Autoimmun, 2014, 52: 139-145. DOI: 10.1016/j.jaut.2013.12.004.
42. Li F, Hotter B, Swierzy M, et al. Generalization after ocular onset in myasthenia gravis: a case series in Germany[J]. J Neurol, 2018, 265(12): 2773-2782. DOI: 10.1007/s00415-018-9056-8.
43. Gengadharan PN, Ong WT, Tan JY, et al. Ocular myasthenia gravis: determining the predictive factors of secondary generalisation[J]. Acta Neurol Belg, 2025, 125(2): 351-358. DOI: 10.1007/s13760-024-02693-9.
44. Marom EM. Imaging thymoma[J]. J Thorac Oncol, 2010, 5(10 Suppl 4): S296-303. DOI: 10.1097/JTO.0b013e3181f209ca.
45. Strange CD, Ahuja J, Shroff GS, et al. Imaging evaluation of thymoma and thymic carcinoma[J/OL]. Front Oncol, 2021, 11: 810419[2022-01-03]. https://pubmed.ncbi.nlm.nih.gov/35047412/. DOI: 10.3389/fonc.2021.810419.
46. Díaz-Manera J, Luna S, Roig C. Ocular ptosis: differential diagnosis and treatment[J]. Curr Opin Neurol, 2018, 31(5): 618-627. DOI: 10.1097/wco.0000000000000600.
47. Dagi LR, Velez FG, Archer SM, et al. Adult strabismus preferred practice pattern?[J]. Ophthalmology, 2020, 127(1): 182-198. DOI: 10.1016/j.ophtha.2019.09.023.
48. Gunton KB, Wasserman BN, DeBenedictis C. Strabismus[J]. Prim Care, 2015, 42(3): 393-407. DOI: 10.1016/j.pop.2015.05.006.
49. Lekskul A, Chotkajornkiat N, Wuthisiri W, et al. Acute acquired comitant esotropia: etiology, clinical course, and management[J]. Clin Ophthalmol, 2021, 15: 1567-1572. DOI: 10.2147/opth.S307951.
50. Ali A, Esmaeil A, Behbehani R. Mitochondrial chronic progressive external ophthalmoplegia[J/OL]. Brain Sci, 2024, 14(2): 135[2024-01-27]. https://pubmed.ncbi.nlm.nih.gov/38391710/. DOI: 10.3390/brainsci14020135.
51. Bartalena L, Gallo D, Tanda ML, et al. Thyroid eye disease: epidemiology, natural history, and risk factors[J]. Ophthalmic Plast Reconstr Surg, 2023, 39(6S): 2-8. DOI: 10.1097/iop.0000000000002467.
52. Julie MS, Shanlee S, Michael K. Thyroid eye disease and ocular myasthenia gravis[J]. Curr Opin Neurol, 2024, 38(1): 71-78. DOI: 10.1097/wco.0000000000001339.
53. Fang Y, Shen B, Dai Q, et al. Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment[J/OL]. Eur J Med Res, 2023, 28(1): 395[2023-10-04]. https://pubmed.ncbi.nlm.nih.gov/37794419/. DOI: 10.1186/s40001-023-01330-0.
54. Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease[J/OL]. BMJ, 2020, 369: 1067[2020-06-16]. https://pubmed.ncbi.nlm.nih.gov/32546500/. DOI: 10.1136/bmj.m1067.
55. Yamashita S. Recent progress in oculopharyngeal muscular dystrophy[J/OL]. J Clin Med, 2021, 10(7): 1375[2021-03-29]. https://pubmed.ncbi.nlm.nih.gov/33805441/. DOI: 10.3390/jcm10071375.
56. Ramdas S, Beeson D, Dong YY. Congenital myasthenic syndromes: increasingly complex[J]. Curr Opin Neurol, 2024, 37(5): 493-501. DOI: 10.1097/wco.0000000000001300.
57. Jagtap SA, Abraham K, Sarada C, et al. Congenital myasthenic syndromes: natural history and long-term prognosis[J]. Ann Indian Acad Neurol, 2013, 16(3): 338-341. DOI: 10.4103/0972-2327.116918.
58. Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes[J/OL]. Ther Adv Neurol Disord, 2023, 16: 17562864231213240[2023-12-26]. https://pubmed.ncbi.nlm.nih.gov/38152089/. DOI: 10.1177/17562864231213240.
59. Punga AR, Maddison P, Heckmann JM, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders[J]. Lancet Neurol, 2022, 21(2): 176-188. DOI: 10.1016/s1474-4422(21)00297-0.
60. Kumar R, Singh BR. Botulinum toxin: a comprehensive review of its molecular architecture and mechanistic action[J/OL]. Int J Mol Sci, 2025, 26(2): 777[2025-01-17]. https://pubmed.ncbi.nlm.nih.gov/39859491/. DOI: 10.3390/ijms26020777.
61. Nestor MS, Han H, Gade A, et al. Botulinum toxin-induced blepharoptosis: anatomy, etiology, prevention, and therapeutic options[J]. J Cosmet Dermatol, 2021, 20(10): 3133-3146. DOI: 10.1111/jocd.14361.
62. Dell'Antonia M, Mugheddu C, Ferreli C, et al. Do not forget about myasthenia gravis when performing botulinum toxin injections[J/OL]. J Eur Acad Dermatol Venereol, 2023, 8: e1070-e1071[2023-04-15]. https://pubmed.ncbi.nlm.nih.gov/37060273/. DOI: 10.1111/jdv.19115.
63. Tamhankar MA, Volpe NJ. Management of acute cranial nerve 3, 4 and 6 palsies: role of neuroimaging[J]. Curr Opin Ophthalmol, 2015, 26(6): 464-468. DOI: 10.1097/icu.0000000000000200.
64. Weidauer S, Hofmann C, Wagner M, et al. Neuroradiological and clinical features in ophthalmoplegia[J]. Neuroradiology, 2019, 61(4): 365-387. DOI: 10.1007/s00234-019-02183-3.
65. Kline LB, Demer JL, Vaphiades MS, et al. Disorders of the fourth cranial nerve[J]. J Neuroophthalmol, 2021, 41(2): 176-193. DOI: 10.1097/wno.0000000000001261.
66. Martin TJ. Horner syndrome: a clinical review[J]. ACS Chem Neurosci, 2017, 9(2): 177-186. DOI: 10.1021/acschemneuro.7b00405.
67. Noioso CM, Bevilacqua L, Acerra GM, et al. Miller Fisher syndrome: an updated narrative review[J/OL]. Front Neurol, 2023, 14: 1250774[2023-08-24]. https://pubmed.ncbi.nlm.nih.gov/37693761/. DOI: 10.3389/fneur.2023.1250774.
68. Wakerley BR, Uncini A, Yuki N. Guillain-Barré and Miller Fisher syndromes--new diagnostic classification[J]. Nat Rev Neurol, 2014, 10(9): 537-544. DOI: 10.1038/nrneurol.2014.138.
69. Soares J, Brigham de Figueiredo M, Prior AR, et al. Jaw winking synkinesis[J/OL]. J Pediatr, 2019, 210: 234[2019-04-19]. https://pubmed.ncbi.nlm.nih.gov/31010588/. DOI: 10.1016/j.jpeds.2019.03.029.
70. Dietz E. Ophthalmoplegia: definition and clinical diagnostic techniques[J]. J Binocul Vis Ocul Motil, 2018, 68(1): 4-6. DOI: 10.1080/2576117x.2017.1416239.
71. Zeppieri M, Ameer MA, Jahngir MU, et al. Meige Syndrome[M/OL]. Treasure Island (FL): StatPearls Publishing, 2025[2025-01-01]. https://pubmed.ncbi.nlm.nih.gov/30020730/.
72. Kerty E, Elsais A, Argov Z, et al. EFNS/ENS guidelines for the treatment of ocular myasthenia[J]. Eur J Neurol, 2014, 21(5): 687-693. DOI: 10.1111/ene.12359.
73. Katz NK, Barohn RJ. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis[J/OL]. Neuropharmacology, 2021, 182: 108303[2020-09-09]. https://pubmed.ncbi.nlm.nih.gov/32918950/. DOI: 10.1016/j.neuropharm.2020.108303.
74. Sharshar T, Porcher R, Demeret S, et al. Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial[J]. JAMA Neurol, 2021, 78(4): 426-433. DOI: 10.1001/jamaneurol.2020.5407.
75. Uzawa A, Suzuki S, Kuwabara S, et al. Impact of early treatment with intravenous high-dose methylprednisolone for ocular myasthenia gravis[J]. Neurotherapeutics, 2023, 20(2): 518-523. DOI: 10.1007/s13311-022-01335-3.
76. Zhang KY, Duan WW, Luo YB, et al. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study[J/OL]. Orphanet J Rare Dis, 2024, 19(1): 19[2024-01-19]. https://pubmed.ncbi.nlm.nih.gov/38243274/. DOI: 10.1186/s13023-024-03025-z.
77. 中華醫學會兒科學分會神經學組. 兒童神經系統疾病糖皮質激素治療專家系列建議之五——重癥肌無力的治療[J]. 中國實用兒科雜志, 2022, 37(5): 340-343. DOI: 10.19538/j.ek2022050606.Neurology Group, Pediatrics Branch, Chinese Medical Association. The fifth expert recommendation in the series of glucocorticoid therapy for children's neurological diseases - treatment of myasthenia gravis[J]. Chin J Pract Pediatr, 2022, 37(5): 340-343. DOI: 10.19538/j.ek2022050606.
78. Benatar M, Sanders DB, Wolfe GI, et al. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial[J]. Ann NY Acad Sci, 2012, 1275: 17-22. DOI: 10.1111/j.1749-6632.2012.06780.x.
79. Witte AS, Cornblath DR, Parry GJ, et al. Azathioprine in the treatment of myasthenia gravis[J]. Ann Neurol, 1984, 15(6): 602-605. DOI: 10.1002/ana.410150615.
80. Duan W, Peng Y, Jin W, et al. Tacrolimus as single-agent immunotherapy and minimal manifestation status in nonthymoma myasthenia gravis[J/OL]. J Immunol Res, 2021, 2021: 9138548[2021-11-20]. https://pubmed.ncbi.nlm.nih.gov/34845439/. DOI: 10.1155/2021/9138548.
81. Fan Z, Lei L, Su S, et al. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis[J]. Ann Clin Transl Neurol, 2023, 10(4): 589-598. DOI: 10.1002/acn3.51746.
82. Ciafaloni E, Nikhar NK, Massey JM, et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis[J]. Neurology, 2000, 55(3): 448-450. DOI: 10.1212/wnl.55.3.448.
83. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis[J/OL]. Cochrane Database Syst Rev, 2007, (4): CD005224[2007-10-17]. https://pubmed.ncbi.nlm.nih.gov/17943844/. DOI: 10.1002/14651858.CD005224.pub2.
84. Chan JW. Mycophenolate mofetil for ocular myasthenia[J]. J Neurol, 2008, 255(4): 510-513. DOI: 10.1007/s00415-008-0718-9.
85. Cornblath WT. Treatment of ocular myasthenia gravis[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(4): 257-259. DOI: 10.22608/APO.2018301.
86. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update[J]. Neurology, 2021, 96(3): 114-122. DOI: 10.1212/wnl.0000000000011124.
87. De Feo LG, Schottlender J, Martelli NA, et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis[J]. Muscle Nerve, 2002, 26(1): 31-36. DOI: 10.1002/mus.10133.
88. Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial[J]. JAMA Neurol, 2022, 79(11): 1105-1112. DOI: 10.1001/jamaneurol.2022.2887.
89. Chuquilin M, Barohn R. Rituximab in newly diagnosed generalized myasthenia gravis: a new treatment paradigm?[J]. JAMA Neurol, 2022, 79(11): 1100-1102. DOI: 10.1001/jamaneurol.2022.2311.
90. Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab[J]. Neuromuscul Disord, 2017, 27(6): 565-568. DOI: 10.1016/j.nmd.2017.03.007.
91. Ma Y, Nie X, Zhu G, et al. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and bayesian network meta-analysis[J]. CNS Drugs, 2024, 38(2): 93-104. DOI: 10.1007/s40263-024-01062-7.
92. Howard JF Jr, Vu T, Li G, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)[J/OL]. Neurotherapeutics, 2024, 21(5): e00378[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/39227284/. DOI: 10.1016/j.neurot.2024.e00378.
93. Ma T, Zhu Y, Zhu R. Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases[J/OL]. Front Immunol, 2024, 15: 1497398[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/39872535/. DOI: 10.3389/fimmu.2024.1497398.
94. Liu Z, Feng H, Yeung SC, et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis[J]. Ann Thorac Surg, 2011, 92(6): 1993-1999. DOI: 10.1016/j.athoracsur.2011.08.001.
95. Liu X, Zhou W, Hu J, et al. Prognostic predictors of remission in ocular myasthenia after thymectomy[J]. J Thorac Dis, 2020, 12(3): 422-430. DOI: 10.21037/jtd.2020.01.17.
96. Wilson L, Davis H. The role of thymoma and thymic hyperplasia as prognostic risk factors for secondary generalisation in adults with ocular myasthenia gravis: a systematic narrative review[J]. Br Ir Orthopt J, 2023, 19(1): 108-119. DOI: 10.22599/bioj.315.
97. Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: association of British Neurologists' management guidelines[J]. Pract Neurol, 2015, 15(3): 199-206. DOI: 10.1136/practneurol-2015-001126.
98. Litwin AS, Patel B, McNab AA, et al. Blepharoptosis surgery in patients with myasthenia gravis[J]. Br J Ophthalmol, 2015, 99(7): 899-902. DOI: 10.1136/bjophthalmol-2014-306335.
99. Witthayaweerasak J, Rattanalert N, Aui-Aree N. Prognostic factors for conversion to generalization in ocular myasthenia gravis[J/OL]. Medicine (Baltimore), 2021, 100(19): e25899[2021-05-14]. https://pubmed.ncbi.nlm.nih.gov/34106649/. DOI: 10.1097/MD.0000000000025899.
100. Wong SH, Huda S, Vincent A, et al. Ocular myasthenia gravis: controversies and updates[J/OL]. Curr Neurol Neurosci Rep, 2014, 14(1): 421[2014-01-01]. https://pubmed.ncbi.nlm.nih.gov/24272275/. DOI: 10.1007/s11910-013-0421-9.
101. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis[J]. Arch Neurol, 2003, 60(2): 243-248. DOI: 10.1001/archneur.60.2.243.
102. Li M, Ge F, Guo R, et al. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis[J/OL]. Ther Adv Neurol Disord, 2019, 12: 1756286419876521[2019-09-14]. https://pubmed.ncbi.nlm.nih.gov/35173803/. DOI: 10.1177/1756286419876521.
103. Ruan Z, Guo R, Zhou H, et al. Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a propensity score analysis[J]. Eur J Neurol, 2022, 29(6): 1805-1814. DOI: 10.1111/ene.15292.
104. 中國罕見病聯盟神經罕見病專業委員會, 中國罕見病聯盟重癥肌無力協作組, 中華醫學會神經病學分會神經肌肉病學組. 中國難治性全身型重癥肌無力診斷和治療專家共識(2024版)[J]. 中華神經科雜志, 2024, 57(8): 840-847. DOI: 10.3760/cma.j.cn113694-20240222-00106.Neurorare Disease Professional Committee of China Rare Disease Alliance, Myasthenia Gravis Collaborative Group of China Rare Disease Alliance, Neuromuscular Disease Group of Neurology Branch, Chinese Medical Association. Expert consensus for diagnosis and treatment of refractory generalized myasthenia gravis in China (2024)[J]. Chin J Neurol, 2024, 57(8): 840-847. DOI: 10.3760/cma.j.cn113694-20240222-00106.

Chinese Journal of Ocular Fundus Diseases

Latest ArticlesChinese expert consensus on the clinical diagnosis and management of ocular myasthenia gravis (2025)

Abstract Full text Figures/Tables Video References Cited by

Format

Content